Unlike traditional flu tests, which involve polymerase chain reaction testing, the new isothermal nucleic acid amplification technology doesn’t require thermo cycling or DNA purification, allowing quicker delivery of results.
“By providing the speed of a rapid test with molecular technology, Alere i delivers clinically meaningful and actionable results to clinicians — enabling them to treat patients more quickly and appropriately,” Avi Pelossof, Alere global president of infectious disease, said in a news release.
Alere is also developing Alere i tests for strep A, C. difficile, respiratory syncytial virus and Chlamydia/gonorrhea.
More Articles on Infection Control:
Zero Adverse Events: How Dignity Health Achieved a New Standard
7 Recent Studies, Stories on Surgical Site Infections
SHEA, APIC, Joint Commission & Others Develop CLABSI Prevention Guidance
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
